175 related articles for article (PubMed ID: 27764892)
1. Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease.
Jin R; Krasinskas A; Le NA; Konomi JV; Holzberg J; Romero R; Vos MB
Pediatr Obes; 2018 Jan; 13(1):23-29. PubMed ID: 27764892
[TBL] [Abstract][Full Text] [Related]
2. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease.
Fitzpatrick E; Dew TK; Quaglia A; Sherwood RA; Mitry RR; Dhawan A
Pediatr Obes; 2012 Dec; 7(6):471-9. PubMed ID: 22962039
[TBL] [Abstract][Full Text] [Related]
3. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Verrijken A; Francque S; Mertens I; Prawitt J; Caron S; Hubens G; Van Marck E; Staels B; Michielsen P; Van Gaal L
Hepatology; 2014 Jan; 59(1):121-9. PubMed ID: 24375485
[TBL] [Abstract][Full Text] [Related]
4. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen Activator Inhibitor-1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight.
Holzberg JR; Jin R; Le NA; Ziegler TR; Brunt EM; McClain CJ; Konomi JV; Arteel GE; Vos MB
J Pediatr Gastroenterol Nutr; 2016 Jun; 62(6):819-23. PubMed ID: 26704864
[TBL] [Abstract][Full Text] [Related]
6. [Insulin-like growth factor-binding protein-1: a new biochemical marker of nonalcoholic fatty liver disease?].
Graffigna MN; Belli SH; de Larrañaga G; Fainboim H; Estepo C; Peres S; García N; Levalle O
Acta Gastroenterol Latinoam; 2009 Mar; 39(1):30-7. PubMed ID: 19408737
[TBL] [Abstract][Full Text] [Related]
7. Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease.
Ercin CN; Dogru T; Genc H; Celebi G; Aslan F; Gurel H; Kara M; Sertoglu E; Tapan S; Bagci S; Rizzo M; Sonmez A
Metab Syndr Relat Disord; 2015 Sep; 13(7):319-25. PubMed ID: 26011302
[TBL] [Abstract][Full Text] [Related]
8. Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease.
Fuchs A; Samovski D; Smith GI; Cifarelli V; Farabi SS; Yoshino J; Pietka T; Chang SW; Ghosh S; Myckatyn TM; Klein S
Gastroenterology; 2021 Sep; 161(3):968-981.e12. PubMed ID: 34004161
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
12. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
13. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
15. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.
Fujimori N; Umemura T; Kimura T; Tanaka N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Usami Y; Sano K; Igarashi K; Matsumoto A; Tanaka E
World J Gastroenterol; 2018 Mar; 24(11):1239-1249. PubMed ID: 29568204
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
[TBL] [Abstract][Full Text] [Related]
17. Increased atherogenic lipoprotein profile in children with non-alcoholic steatohepatitis.
Castillo-Leon E; Connelly MA; Konomi JV; Caltharp S; Cleeton R; Vos MB
Pediatr Obes; 2020 Sep; 15(9):e12648. PubMed ID: 32367624
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
[TBL] [Abstract][Full Text] [Related]
19. Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome.
de Larrañaga G; Wingeyer SP; Graffigna M; Belli S; Bendezú K; Alvarez S; Levalle O; Fainboim H
Clin Appl Thromb Hemost; 2008 Jul; 14(3):319-24. PubMed ID: 18160600
[TBL] [Abstract][Full Text] [Related]
20. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
